MeSH term
Frequency | Condition_Probility | English Abstract | 47 | 0.0 |
Humans | 674 | 0.0 |
Translocation, Genetic | 2 | 0.0 |
Antigens, CD57/*immunology | 2 | 33.0 |
Biological Markers | 4 | 0.0 |
Cell Division | 26 | 0.0 |
Cells, Cultured | 70 | 0.0 |
Cytotoxicity, Immunologic | 19 | 1.0 |
Enterotoxins/*immunology/pharmacology | 2 | 25.0 |
Interferon Type II/biosynthesis | 14 | 3.0 |
Lymphocyte Activation/immunology | 13 | 2.0 |
Staphylococcus aureus/*immunology | 45 | 49.0 |
T-Lymphocyte Subsets/immunology | 7 | 1.0 |
Adolescent | 127 | 0.0 |
Adult | 191 | 0.0 |
Animals | 296 | 0.0 |
Brazil/epidemiology | 4 | 4.0 |
Child | 114 | 0.0 |
Enzyme-Linked Immunosorbent Assay | 64 | 1.0 |
Feces/parasitology | 13 | 30.0 |
Female | 244 | 0.0 |
Male | 223 | 0.0 |
Prevalence | 22 | 1.0 |
Research Support, Non-U.S. Gov't | 410 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 136 | 0.0 |
Schistosoma mansoni/*immunology | 57 | 80.0 |
Comparative Study | 86 | 0.0 |
Enzyme-Linked Immunosorbent Assay/methods | 11 | 4.0 |
Schistosomiasis japonica/*diagnosis | 6 | 85.0 |
Aged | 75 | 0.0 |
Antibodies, Helminth/*immunology | 8 | 88.0 |
Child, Preschool | 57 | 0.0 |
China/epidemiology | 4 | 2.0 |
Follow-Up Studies | 17 | 0.0 |
Immunoglobulin E/immunology | 2 | 3.0 |
Immunoglobulin G/immunology | 5 | 1.0 |
Infant | 35 | 0.0 |
Infant, Newborn | 16 | 0.0 |
Middle Aged | 134 | 0.0 |
Schistosoma japonicum/*immunology | 19 | 90.0 |
*Antigen Presentation | 4 | 2.0 |
Binding Sites | 27 | 0.0 |
Lymphocyte Activation | 83 | 2.0 |
Mice | 112 | 0.0 |
Models, Molecular | 9 | 0.0 |
Protein Binding | 12 | 0.0 |
Cognition Disorders/etiology | 2 | 15.0 |
Food Contamination | 3 | 10.0 |
Risk Assessment | 4 | 0.0 |
Antigens, Helminth/*immunology | 48 | 82.0 |
Ovum/*immunology | 10 | 83.0 |
Schistosomiasis mansoni/complications | 2 | 100.0 |
Up-Regulation | 3 | 0.0 |
Superantigens/genetics/*immunology/metabolism | 3 | 100.0 |
T-Lymphocytes/*immunology | 43 | 1.0 |
Tumor Cells, Cultured | 34 | 0.0 |
Xenograft Model Antitumor Assays | 3 | 1.0 |
*Apoptosis | 3 | 0.0 |
Calcium/metabolism | 3 | 0.0 |
Cyclic AMP/metabolism | 2 | 0.0 |
Dose-Response Relationship, Drug | 12 | 0.0 |
Endocannabinoids | 2 | 8.0 |
Hydrolysis | 4 | 0.0 |
Kinetics | 23 | 0.0 |
Models, Biological | 6 | 0.0 |
Rats | 20 | 0.0 |
Cell Division/immunology | 8 | 2.0 |
Dose-Response Relationship, Immunologic | 15 | 2.0 |
Enterotoxins/*immunology | 53 | 71.0 |
Histocompatibility Antigens Class II/metabolism | 8 | 10.0 |
Mice, Inbred Strains | 7 | 0.0 |
Species Specificity | 6 | 0.0 |
Spleen/immunology | 4 | 2.0 |
Superantigens/*immunology | 44 | 55.0 |
Risk Factors | 22 | 0.0 |
Seawater/*adverse effects | 2 | 100.0 |
Chronic Disease | 26 | 1.0 |
Exertion | 2 | 2.0 |
Prognosis | 8 | 0.0 |
Treatment Outcome | 16 | 0.0 |
Age of Onset | 3 | 0.0 |
Alleles | 9 | 0.0 |
Genotype | 9 | 0.0 |
Phenotype | 11 | 0.0 |
alpha-Thalassemia/*genetics | 5 | 35.0 |
Radioimmunoassay | 4 | 0.0 |
*Swimming | 2 | 25.0 |
Base Sequence | 40 | 0.0 |
Chickens | 2 | 0.0 |
DNA Primers | 9 | 0.0 |
Enterotoxins/*genetics | 4 | 57.0 |
Food Microbiology | 10 | 34.0 |
Phylogeny | 5 | 0.0 |
Polymerase Chain Reaction/veterinary | 2 | 5.0 |
Staphylococcus aureus/*genetics/pathogenicity | 2 | 100.0 |
Antibody Specificity | 15 | 1.0 |
Cattle | 6 | 0.0 |
Drug Synergism | 3 | 0.0 |
Immunization | 9 | 2.0 |
Interleukin-2/*pharmacology | 3 | 1.0 |
Lung Neoplasms/secondary | 2 | 2.0 |
Mice, Inbred C57BL | 26 | 0.0 |
Neoplasm Transplantation | 5 | 0.0 |
Recombinant Proteins/pharmacology | 7 | 0.0 |
Transfection | 19 | 0.0 |
Aged, 80 and over | 24 | 0.0 |
Electrophoresis, Agar Gel | 4 | 0.0 |
Polymerase Chain Reaction | 26 | 0.0 |
Biological Transport | 3 | 0.0 |
Cell Line | 53 | 0.0 |
*Epitopes | 3 | 2.0 |
Immune Sera/immunology | 4 | 2.0 |
DNA, Bacterial/analysis | 3 | 5.0 |
*Disease Outbreaks | 4 | 6.0 |
Electrophoresis, Gel, Pulsed-Field | 2 | 0.0 |
Enterotoxins/genetics | 3 | 50.0 |
Feces/microbiology | 2 | 3.0 |
RNA, Messenger/analysis | 4 | 0.0 |
Rabbits | 20 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 4 | 0.0 |
Superantigens/*genetics | 2 | 100.0 |
Amino Acid Sequence | 39 | 0.0 |
Chromosomes, Human, Pair 7 | 2 | 1.0 |
Cloning, Molecular | 16 | 0.0 |
Hamsters | 13 | 0.0 |
In Situ Hybridization | 2 | 0.0 |
Molecular Sequence Data | 68 | 0.0 |
Protein Structure, Tertiary | 10 | 0.0 |
RNA, Messenger/biosynthesis | 2 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 52 | 0.0 |
Sequence Alignment | 5 | 0.0 |
Sequence Homology, Amino Acid | 10 | 0.0 |
Tissue Distribution | 6 | 0.0 |
Amino Acid Substitution | 2 | 0.0 |
Enterotoxins/chemistry/immunology/*metabolism | 2 | 100.0 |
Mutation | 9 | 0.0 |
Protein Conformation | 11 | 0.0 |
Structure-Activity Relationship | 11 | 0.0 |
Age Factors | 19 | 0.0 |
Antibodies, Helminth/*blood | 23 | 67.0 |
Cohort Studies | 9 | 0.0 |
Ethiopia/epidemiology | 2 | 33.0 |
Immunoglobulin E/blood | 10 | 7.0 |
Immunoglobulin G/blood/classification | 2 | 33.0 |
Immunoglobulin Isotypes/blood | 6 | 31.0 |
Ovum/immunology | 41 | 85.0 |
Praziquantel/therapeutic use | 11 | 84.0 |
Sex Factors | 11 | 0.0 |
CA-15-3 Antigen/*immunology | 3 | 5.0 |
Enterotoxins/genetics/immunology | 2 | 100.0 |
Escherichia coli | 2 | 0.0 |
Flow Cytometry | 26 | 0.0 |
Hybridomas/immunology | 3 | 2.0 |
*Immunotherapy | 2 | 1.0 |
Killer Cells, Lymphokine-Activated/immunology | 2 | 3.0 |
Mice, SCID | 8 | 1.0 |
Molecular Weight | 9 | 0.0 |
Protein Folding | 3 | 0.0 |
Superantigens/*immunology/therapeutic use | 2 | 100.0 |
Immunoenzyme Techniques | 3 | 0.0 |
Antibodies, Monoclonal/chemistry | 2 | 2.0 |
*Immunoconjugates | 2 | 0.0 |
Leukocytes, Mononuclear/immunology | 12 | 4.0 |
Mice, Inbred BALB C | 13 | 0.0 |
Magnetic Resonance Imaging | 5 | 0.0 |
Retrospective Studies | 16 | 0.0 |
Staphylococcal Infections/*complications | 2 | 66.0 |
Staphylococcus aureus/isolation & purification | 2 | 18.0 |
Disease Progression | 3 | 0.0 |
Enterotoxins/immunology | 26 | 47.0 |
Immunoglobulin E/analysis | 3 | 5.0 |
Staphylococcus aureus/*isolation & purification | 4 | 50.0 |
Enterotoxins/*biosynthesis | 9 | 69.0 |
Temperature | 7 | 0.0 |
Time Factors | 29 | 0.0 |
Antibody Specificity/immunology | 2 | 3.0 |
Immunoglobulin E/blood/immunology | 2 | 18.0 |
Severity of Illness Index | 9 | 0.0 |
Statistics | 2 | 0.0 |
Enterotoxins/genetics/*immunology | 7 | 77.0 |
Superantigens/immunology | 10 | 21.0 |
Amino Acids/analysis | 2 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 16 | 0.0 |
Staphylococcal Food Poisoning/prevention & control | 2 | 100.0 |
Antibodies, Monoclonal/immunology | 14 | 0.0 |
Antigens, CD/*physiology | 4 | 1.0 |
Antigens, CD18/physiology | 2 | 16.0 |
Cell Separation | 10 | 0.0 |
Interferon Type II/physiology | 2 | 2.0 |
Statistics, Nonparametric | 5 | 0.0 |
T-Lymphocytes/cytology/*immunology | 4 | 3.0 |
Arthritis, Rheumatoid/*immunology | 3 | 1.0 |
Enterotoxins/*pharmacology | 29 | 53.0 |
Interleukin-1/pharmacology | 4 | 0.0 |
Leukocytes, Mononuclear/*metabolism | 6 | 4.0 |
Lipopolysaccharides/pharmacology | 8 | 0.0 |
Diagnosis, Differential | 4 | 0.0 |
*Chromosomes, Human, Pair 11 | 5 | 0.0 |
Pregnancy | 18 | 0.0 |
*Prenatal Diagnosis | 6 | 2.0 |
Acute Disease | 16 | 0.0 |
Schistosomiasis mansoni/*immunology | 30 | 85.0 |
Antigens, Helminth | 5 | 62.0 |
Interferon Type II/analysis | 3 | 3.0 |
Interleukin-5/analysis | 2 | 15.0 |
Mitogens | 3 | 4.0 |
Phytohemagglutinins | 3 | 3.0 |
Schistosoma haematobium/*immunology | 11 | 84.0 |
Schistosomiasis haematobia/blood/epidemiology/*immunology | 2 | 100.0 |
Zimbabwe/epidemiology | 2 | 13.0 |
Asia, Southeastern/epidemiology | 4 | 57.0 |
Genetic Screening/*methods | 2 | 1.0 |
Globins/*genetics | 3 | 2.0 |
Heterozygote | 6 | 0.0 |
Polymerase Chain Reaction/*methods | 5 | 0.0 |
Taiwan | 4 | 2.0 |
alpha-Thalassemia/*diagnosis/epidemiology/*genetics | 2 | 100.0 |
Immunotherapy | 4 | 1.0 |
Genetic Vectors | 2 | 0.0 |
T-Lymphocytes, Cytotoxic/*immunology | 12 | 2.0 |
Cytokines/biosynthesis | 6 | 1.0 |
Enzyme Activation/immunology | 2 | 1.0 |
Lymphocyte Activation/*immunology | 13 | 3.0 |
Lymphocyte Specific Protein Tyrosine Kinase p56(lck)/metabolism | 2 | 3.0 |
Phosphorylation | 5 | 0.0 |
Receptors, Antigen, T-Cell/metabolism | 2 | 1.0 |
Signal Transduction/*immunology | 3 | 0.0 |
Tyrosine/metabolism | 2 | 0.0 |
Anthelmintics/therapeutic use | 3 | 60.0 |
Blotting, Western | 13 | 0.0 |
Disease Susceptibility | 6 | 0.0 |
Sex Distribution | 4 | 1.0 |
Sequence Analysis, DNA | 3 | 0.0 |
RNA, Messenger/genetics | 2 | 0.0 |
Chorionic Villi Sampling | 3 | 6.0 |
Globins/genetics | 2 | 1.0 |
Pedigree | 3 | 0.0 |
*Polymerase Chain Reaction | 2 | 0.0 |
Reference Values | 7 | 0.0 |
alpha-Thalassemia/blood/*diagnosis | 2 | 100.0 |
*Bacteriological Techniques | 2 | 22.0 |
DNA Fingerprinting | 3 | 2.0 |
*Food Microbiology | 7 | 46.0 |
Genes, Bacterial | 2 | 1.0 |
Latex Fixation Tests/methods | 2 | 40.0 |
Polymerase Chain Reaction/methods | 2 | 0.0 |
Cell Membrane/metabolism | 2 | 0.0 |
DNA, Complementary/metabolism | 2 | 0.0 |
Epithelium/metabolism | 3 | 0.0 |
Escherichia coli/metabolism | 2 | 0.0 |
Glycosylation | 4 | 0.0 |
Hela Cells | 3 | 0.0 |
Microscopy, Confocal | 2 | 0.0 |
Multigene Family | 3 | 0.0 |
Peptides/chemistry | 3 | 0.0 |
RNA, Messenger/metabolism | 4 | 0.0 |
Recombinant Proteins/chemistry | 2 | 0.0 |
Bacterial Toxins/*blood | 2 | 100.0 |
Staphylococcus aureus/*metabolism | 12 | 52.0 |
Analysis of Variance | 4 | 0.0 |
Immunoblotting | 5 | 0.0 |
Immunoglobulin G/*blood | 9 | 14.0 |
Oxamniquine/therapeutic use | 3 | 100.0 |
Schistosomiasis mansoni/drug therapy/*immunology | 2 | 100.0 |
Schistosomicides/therapeutic use | 5 | 100.0 |
Streptococcus pyogenes/*immunology | 2 | 10.0 |
Tumor Necrosis Factor-alpha/biosynthesis/genetics | 3 | 5.0 |
Antigen Presentation | 7 | 2.0 |
Apoptosis/*immunology | 3 | 1.0 |
Binding Sites, Antibody | 3 | 0.0 |
Cell Line, Transformed | 3 | 0.0 |
Ligands | 5 | 0.0 |
*Lymphocyte Activation | 33 | 2.0 |
Macromolecular Substances | 6 | 0.0 |
Protein Binding/immunology | 3 | 1.0 |
Staphylococcus aureus/immunology | 28 | 26.0 |
Antibodies, Bacterial/*immunology | 3 | 12.0 |
*Bacterial Toxins | 35 | 24.0 |
Superantigens/chemistry/*immunology | 2 | 50.0 |
Tumor Necrosis Factor-alpha/biosynthesis | 7 | 1.0 |
Antigens, Helminth/immunology | 19 | 59.0 |
Immunoglobulin Isotypes/*blood | 4 | 50.0 |
Chest Pain/blood | 2 | 66.0 |
Comorbidity | 3 | 1.0 |
Hypertension/epidemiology | 2 | 4.0 |
Monocyte Chemoattractant Protein-1/*blood | 2 | 14.0 |
Recurrence | 9 | 0.0 |
Disease Outbreaks | 3 | 5.0 |
Japan/epidemiology | 4 | 1.0 |
Polymorphism, Restriction Fragment Length | 3 | 0.0 |
Staphylococcal Food Poisoning/*epidemiology | 2 | 100.0 |
Antigen-Presenting Cells/immunology | 8 | 2.0 |
Enterotoxins/chemistry/*immunology | 2 | 66.0 |
Evolution | 2 | 0.0 |
HLA-D Antigens/immunology | 3 | 7.0 |
T-Lymphocytes/chemistry/*immunology | 2 | 14.0 |
Angina Pectoris/blood | 2 | 14.0 |
Coculture Techniques | 4 | 0.0 |
Lymphocytes/immunology | 5 | 1.0 |
Predictive Value of Tests | 9 | 0.0 |
Chromosome Mapping | 5 | 0.0 |
Chromosomes, Human, Pair 3 | 2 | 1.0 |
DNA, Complementary/genetics | 5 | 0.0 |
Organ Specificity | 2 | 0.0 |
Case-Control Studies | 19 | 0.0 |
Cuba | 3 | 25.0 |
Logistic Models | 4 | 0.0 |
Transients and Migrants | 2 | 18.0 |
Food Contamination/*analysis | 2 | 13.0 |
Biological Markers/analysis | 2 | 0.0 |
Eosinophilia | 2 | 50.0 |
Immunoglobulin E/*analysis | 2 | 10.0 |
Receptors, Fc/immunology | 2 | 4.0 |
Staphylococcal Protein A/immunology | 3 | 37.0 |
Staphylococcus/*metabolism | 2 | 100.0 |
Granuloma/immunology/pathology | 2 | 28.0 |
Mice, Knockout | 3 | 0.0 |
Schistosoma mansoni/immunology | 16 | 59.0 |
Th1 Cells/immunology | 3 | 1.0 |
Th2 Cells/*immunology | 2 | 1.0 |
Carrier State/*microbiology | 2 | 25.0 |
Enterotoxins/analysis | 4 | 80.0 |
Hemagglutination Tests | 8 | 9.0 |
Antigens, Bacterial/*pharmacology | 5 | 45.0 |
Brefeldin A/pharmacology | 2 | 2.0 |
In Vitro | 39 | 0.0 |
Leukocytes, Mononuclear/drug effects/*physiology | 2 | 22.0 |
Tumor Necrosis Factor-alpha/physiology | 3 | 1.0 |
Antibodies, Helminth/*analysis | 4 | 57.0 |
Antigens, Helminth/*analysis | 6 | 85.0 |
Egypt | 7 | 16.0 |
Enzyme-Linked Immunosorbent Assay/*methods | 8 | 5.0 |
Schistosomiasis/*diagnosis | 5 | 83.0 |
Cross Reactions | 13 | 1.0 |
Schistosomiasis japonica/diagnosis | 2 | 66.0 |
History, 19th Century | 2 | 6.0 |
United States | 8 | 0.0 |
Electrophoresis/methods | 2 | 2.0 |
Immunohistochemistry | 7 | 0.0 |
Schistosoma japonicum/growth & development/*immunology | 2 | 100.0 |
Sensitivity and Specificity | 34 | 1.0 |
Antigens, Helminth/*metabolism | 2 | 66.0 |
Anti-Bacterial Agents/*pharmacology | 3 | 2.0 |
Lung/*cytology/drug effects | 2 | 25.0 |
Staphylococcal Protein A/pharmacology | 3 | 42.0 |
Tumor Necrosis Factor-alpha/pharmacology | 4 | 0.0 |
Sweden | 2 | 0.0 |
Gene Deletion | 7 | 0.0 |
Prenatal Diagnosis | 2 | 1.0 |
Immunoglobulin G/*analysis | 2 | 2.0 |
Schistosomiasis mansoni/blood/*diagnosis | 2 | 100.0 |
Schistosomiasis mansoni/*diagnosis | 7 | 87.0 |
Antigens, Bacterial/*immunology | 14 | 12.0 |
Chemotaxis, Leukocyte | 3 | 1.0 |
Concanavalin A/pharmacology | 6 | 2.0 |
*Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 2 | 7.0 |
Lymphocyte Activation/drug effects/*immunology | 4 | 9.0 |
Phytohemagglutinins/pharmacology | 8 | 1.0 |
Receptors, Antigen, T-Cell, alpha-beta/*genetics | 2 | 2.0 |
Antibodies, Bacterial/blood | 3 | 4.0 |
Immunoglobulin E/*blood | 5 | 9.0 |
Epitopes/immunology | 6 | 1.0 |
False Positive Reactions | 2 | 0.0 |
*Helminth Proteins | 3 | 42.0 |
Oxidation-Reduction | 2 | 0.0 |
Cell Cycle | 2 | 0.0 |
Cell Death | 2 | 0.0 |
Mitosis | 3 | 0.0 |
Protein p53/metabolism | 2 | 0.0 |
Immunoglobulin G/analysis | 5 | 1.0 |
Immunoglobulin M/analysis | 5 | 2.0 |
Seroepidemiologic Studies | 3 | 2.0 |
Cyclosporine/*pharmacology | 2 | 1.0 |
Immunosuppressive Agents/*pharmacology | 4 | 1.0 |
Tumor Necrosis Factor-alpha/immunology | 3 | 2.0 |
Allergens/immunology | 3 | 4.0 |
Eosinophil Granule Proteins | 2 | 0.0 |
Plasmids | 5 | 0.0 |
Spain/epidemiology | 2 | 1.0 |
Superantigens | 2 | 40.0 |
Antigens, CD2 | 2 | 0.0 |
Receptors, Antigen, T-Cell, alpha-beta | 2 | 5.0 |
T-Lymphocyte Subsets/*immunology | 9 | 1.0 |
Antibodies, Helminth/blood | 11 | 55.0 |
Immunity, Cellular | 14 | 2.0 |
Schistosomiasis mansoni/drug therapy/epidemiology/*immunology | 2 | 100.0 |
Anti-Bacterial Agents/pharmacology | 2 | 1.0 |
Cytokines/*biosynthesis | 7 | 1.0 |
Enzyme Inhibitors/pharmacology | 3 | 0.0 |
Interleukin-2/biosynthesis | 15 | 3.0 |
Interleukin-6/biosynthesis | 2 | 0.0 |
Interferon Type II/*biosynthesis | 21 | 13.0 |
Interleukin-4/biosynthesis | 4 | 2.0 |
Immunoglobulin A/*blood | 2 | 7.0 |
Immunoglobulin M/*blood | 2 | 5.0 |
Reproducibility of Results | 4 | 0.0 |
Oligosaccharides/*immunology | 2 | 22.0 |
Flow Cytometry/methods | 2 | 0.0 |
Superantigens/blood/*immunology | 2 | 100.0 |
Schistosomiasis haematobia/*diagnosis/drug therapy | 2 | 100.0 |
Cell Nucleus/metabolism | 3 | 0.0 |
Adjuvants, Immunologic/*pharmacology | 2 | 1.0 |
Interleukin-2/*biosynthesis | 7 | 4.0 |
Thalidomide/*pharmacology | 3 | 17.0 |
Antibodies, Helminth/*biosynthesis | 6 | 85.0 |
Cytokines/blood | 3 | 1.0 |
Helminth Proteins/*immunology | 4 | 57.0 |
Antibodies, Monoclonal/pharmacology | 6 | 0.0 |
Antigens, CD40/*immunology | 2 | 5.0 |
Antigens, CD80/*immunology | 2 | 4.0 |
Dendritic Cells/*immunology | 2 | 0.0 |
Histocompatibility Antigens Class II/*immunology | 8 | 4.0 |
Histocompatibility Antigens Class II/*metabolism | 3 | 5.0 |
Mutagenesis, Site-Directed | 8 | 0.0 |
Cross-Sectional Studies | 3 | 0.0 |
Gene Library | 2 | 0.0 |
Immunoglobulin A/blood | 2 | 1.0 |
Philippines | 3 | 10.0 |
Schistosomiasis japonica/*immunology | 7 | 100.0 |
Immunoglobulin E/*blood/immunology | 2 | 40.0 |
Praziquantel/pharmacology | 2 | 100.0 |
Disease Models, Animal | 8 | 0.0 |
Immunoglobulin G/blood | 11 | 3.0 |
Liver/pathology | 2 | 1.0 |
Parasite Egg Count | 22 | 61.0 |
Schistosoma mansoni/growth & development/*immunology | 5 | 83.0 |
B-Lymphocytes/*immunology | 8 | 0.0 |
Biotin | 2 | 3.0 |
HLA-DR Antigens/immunology | 4 | 1.0 |
Precipitin Tests | 2 | 0.0 |
Antibodies, Bacterial/*blood | 3 | 6.0 |
Fetal Blood/*immunology | 2 | 2.0 |
Immunophenotyping | 7 | 0.0 |
Ionomycin/pharmacology | 2 | 0.0 |
Killer Cells, Natural/immunology | 5 | 1.0 |
Tetradecanoylphorbol Acetate/pharmacology | 6 | 0.0 |
Asia, Southeastern/ethnology | 3 | 18.0 |
European Continental Ancestry Group | 2 | 0.0 |
Antigens, Helminth/*blood | 4 | 50.0 |
Schistosomiasis mansoni/*immunology/parasitology | 2 | 50.0 |
Th1 Cells/*immunology | 3 | 2.0 |
Health Surveys | 2 | 2.0 |
Questionnaires | 3 | 0.0 |
Lymphocyte Count | 2 | 0.0 |
*Avian Proteins | 2 | 2.0 |
CHO Cells | 7 | 0.0 |
COS Cells | 2 | 0.0 |
Culture Media, Conditioned | 2 | 0.0 |
Growth Substances/*metabolism | 2 | 1.0 |
Protein-Tyrosine Kinase/*metabolism | 2 | 0.0 |
Recombinant Fusion Proteins/metabolism | 3 | 0.0 |
Blotting, Southern | 4 | 0.0 |
Recombination, Genetic | 3 | 0.0 |
*Superantigens | 25 | 55.0 |
Virulence | 4 | 1.0 |
Enterotoxins/biosynthesis/*immunology | 2 | 100.0 |
HLA-DR Antigens/metabolism | 3 | 2.0 |
Intercellular Adhesion Molecule-1/metabolism | 3 | 1.0 |
Interferon Type II/pharmacology | 2 | 0.0 |
Microscopy, Electron | 3 | 0.0 |
Organ Culture Techniques | 3 | 0.0 |
Staphylococcus aureus/*immunology/isolation & purification/metabolism | 2 | 100.0 |
Hydrocortisone/pharmacology | 2 | 2.0 |
Leukocytes/*immunology | 2 | 1.0 |
Neutralization Tests | 4 | 0.0 |
*Staphylococcus aureus | 8 | 38.0 |
Enterotoxins/*analysis | 4 | 57.0 |
Sudden Infant Death/*etiology | 2 | 25.0 |
Immunoglobulin G/biosynthesis | 6 | 3.0 |
Lymphocytes/metabolism | 2 | 0.0 |
Mice, Inbred CBA | 11 | 3.0 |
*Disease Models, Animal | 2 | 0.0 |
Tumor Necrosis Factor-alpha/analysis | 2 | 0.0 |
Immune Sera/pharmacology | 3 | 3.0 |
Receptors, Antigen, T-Cell/immunology | 3 | 1.0 |
Spleen/cytology/immunology | 2 | 3.0 |
Interleukin-10/*biosynthesis | 2 | 3.0 |
Antigens, Helminth/*urine | 2 | 100.0 |
Interleukin-10/biosynthesis | 2 | 1.0 |
Interleukin-12/pharmacology | 2 | 4.0 |
Leukocytes, Mononuclear/*immunology | 10 | 5.0 |
Epidural Space | 4 | 66.0 |
China | 5 | 1.0 |
DNA Mutational Analysis | 3 | 0.0 |
Sequence Deletion/genetics | 2 | 1.0 |
Aging/immunology | 2 | 3.0 |
Dermatitis, Atopic/*immunology | 3 | 7.0 |
Staphylococcus/*immunology | 3 | 50.0 |
Antigen Presentation/*immunology | 5 | 5.0 |
Histocompatibility Antigens Class II/immunology | 10 | 5.0 |
Recombinant Fusion Proteins/immunology | 2 | 1.0 |
Antibodies, Helminth/immunology | 8 | 61.0 |
Cross Reactions/immunology | 2 | 4.0 |
Protein Engineering | 2 | 2.0 |
Solubility | 10 | 0.0 |
T-Lymphocytes/immunology | 26 | 1.0 |
Enterotoxins/pharmacology | 22 | 35.0 |
Exotoxins/*pharmacology | 4 | 16.0 |
Granulocyte Colony-Stimulating Factor/*secretion | 2 | 50.0 |
Staphylococcus aureus/*pathogenicity | 4 | 36.0 |
Conserved Sequence | 2 | 0.0 |
Praziquantel/*therapeutic use | 9 | 90.0 |
Receptors, Antigen, T-Cell, alpha-beta/analysis | 2 | 4.0 |
Evaluation Studies | 10 | 1.0 |
Immunoglobulin M/blood | 6 | 4.0 |
CD8-Positive T-Lymphocytes/*immunology | 3 | 0.0 |
Down-Regulation | 4 | 0.0 |
Psoriasis/*immunology | 2 | 11.0 |
Receptors, Antigen, T-Cell, alpha-beta/immunology | 6 | 9.0 |
Antibodies, Anti-Idiotypic/*blood | 2 | 40.0 |
Superantigens/blood | 2 | 100.0 |
HLA-DR4 Antigen/genetics/*immunology | 2 | 40.0 |
Receptors, Antigen, T-Cell, alpha-beta/genetics/*immunology | 2 | 11.0 |
Recombinant Fusion Proteins/genetics/immunology | 2 | 4.0 |
Superantigens/genetics/*immunology | 2 | 50.0 |
Enterotoxins/metabolism | 2 | 28.0 |
Kenya | 3 | 6.0 |
Cytokines/immunology | 4 | 2.0 |
Leukocyte Count | 8 | 0.0 |
Staphylococcal Infections/microbiology | 2 | 22.0 |
Staphylococcal Infections/*microbiology | 2 | 40.0 |
Interferon Type II/*immunology | 2 | 5.0 |
Prospective Studies | 8 | 0.0 |
Interferon Inducers/*pharmacology | 4 | 22.0 |
Membrane Glycoproteins/genetics/*immunology | 2 | 3.0 |
Mice, Transgenic | 6 | 0.0 |
Spleen/drug effects/immunology | 2 | 33.0 |
Staphylococcus aureus | 20 | 31.0 |
Superantigens/pharmacology | 6 | 24.0 |
Monocytes/*physiology | 3 | 1.0 |
Antibodies, Monoclonal | 12 | 0.0 |
Enterotoxins/genetics/*immunology/metabolism | 2 | 100.0 |
Interferon Type II/immunology | 4 | 4.0 |
Recombinant Proteins/immunology | 3 | 0.0 |
Immunoglobulin E/*immunology | 5 | 20.0 |
Radioallergosorbent Test | 3 | 6.0 |
Seasons | 4 | 2.0 |
Infusions, Intravenous | 3 | 0.0 |
Antigens, Surface/analysis | 2 | 0.0 |
Cell Adhesion | 6 | 0.0 |
Interleukin-1/metabolism | 3 | 1.0 |
Enterotoxins/immunology/pharmacology | 2 | 100.0 |
Receptors, Antigen, T-Cell, alpha-beta/drug effects/*immunology | 2 | 100.0 |
Superantigens/immunology/*pharmacology | 2 | 100.0 |
Antibodies, Helminth/*blood/immunology | 2 | 100.0 |
*Breast Feeding | 2 | 3.0 |
Schistosomiasis mansoni/immunology | 5 | 83.0 |
Cell Survival | 2 | 0.0 |
Trans-Activation (Genetics) | 2 | 0.0 |
Cell Differentiation/immunology | 2 | 0.0 |
Conserved Sequence/immunology | 2 | 40.0 |
Enterotoxins/metabolism/*pharmacology | 3 | 75.0 |
Gene Expression Regulation/immunology | 2 | 1.0 |
Cytokines/*physiology | 2 | 1.0 |
Fluorescent Antibody Technique | 11 | 0.0 |
HLA-DR Antigens/analysis | 5 | 0.0 |
Immune Tolerance/*physiology | 2 | 14.0 |
Receptors, Interleukin-2/analysis | 2 | 0.0 |
Signal Processing, Computer-Assisted | 2 | 4.0 |
Antibodies, Monoclonal/therapeutic use | 4 | 2.0 |
Enterotoxins/*therapeutic use | 3 | 100.0 |
Immunotoxins/*therapeutic use | 2 | 4.0 |
Superantigens/*therapeutic use | 6 | 100.0 |
Interferon Inducers/pharmacology | 7 | 35.0 |
Lymphocyte Activation/drug effects | 14 | 2.0 |
Cell Division/drug effects | 8 | 0.0 |
Lymphocyte Activation/*drug effects | 12 | 3.0 |
Receptors, Antigen, T-Cell, alpha-beta/metabolism | 2 | 6.0 |
Superantigens/*pharmacology | 10 | 35.0 |
Schistosomiasis haematobia/drug therapy/*immunology | 3 | 100.0 |
Antibody Formation | 4 | 0.0 |
Antigens, Protozoan/*immunology | 2 | 5.0 |
Schistosomiasis haematobia/*immunology | 4 | 66.0 |
Antigens, Differentiation/*physiology | 2 | 2.0 |
*Clonal Anergy | 2 | 6.0 |
T-Lymphocytes/drug effects/*immunology | 7 | 4.0 |
Antibodies, Monoclonal/*immunology | 4 | 0.0 |
*Antibody-Dependent Cell Cytotoxicity | 2 | 4.0 |
Antigens, CD/immunology | 3 | 0.0 |
HL-60 Cells | 2 | 0.0 |
Stimulation, Chemical | 5 | 1.0 |
HLA-D Antigens/genetics/*immunology | 2 | 28.0 |
Peptides/chemical synthesis/immunology | 2 | 4.0 |
Antigen-Antibody Complex/*immunology | 3 | 3.0 |
Granuloma/*immunology | 3 | 27.0 |
Culture Media, Conditioned/chemistry | 2 | 4.0 |
Cytokines/metabolism | 4 | 0.0 |
Dimerization | 2 | 0.0 |
HLA-D Antigens/*metabolism | 3 | 14.0 |
Colonic Neoplasms/immunology | 2 | 9.0 |
Cercopithecus aethiops | 2 | 0.0 |
Fibrinolysis | 2 | 1.0 |
Nose/*microbiology | 2 | 40.0 |
Cyclosporine/pharmacology | 3 | 1.0 |
Interleukin-2/pharmacology | 3 | 0.0 |
Receptors, Interleukin-2/metabolism | 2 | 1.0 |
Signal Transduction | 5 | 0.0 |
CD4-Positive T-Lymphocytes/*immunology | 10 | 1.0 |
HIV-1/*immunology | 2 | 0.0 |
Emigration and Immigration | 3 | 6.0 |
Histocompatibility Antigens Class I/immunology | 2 | 1.0 |
Population Surveillance/methods | 2 | 18.0 |
Receptors, Antigen, T-Cell, alpha-beta/*immunology | 4 | 7.0 |
T-Lymphocytes, Helper-Inducer/*immunology | 3 | 1.0 |
Antigens, Protozoan/immunology | 3 | 9.0 |
Intestinal Diseases, Parasitic/immunology | 2 | 100.0 |
Liver Diseases, Parasitic/immunology | 2 | 100.0 |
Splenic Diseases/immunology | 3 | 100.0 |
Schistosomiasis mansoni/epidemiology/*immunology | 3 | 100.0 |
Homozygote | 2 | 0.0 |
Mice, Inbred C3H | 4 | 0.0 |
Mycoplasma/*immunology | 3 | 50.0 |
Polymorphism, Genetic | 3 | 0.0 |
Antigen-Presenting Cells/metabolism | 2 | 11.0 |
Enterotoxins/*metabolism | 10 | 66.0 |
Gene Expression | 5 | 0.0 |
HLA-DR Antigens/*metabolism | 4 | 6.0 |
Superantigens/*metabolism | 4 | 57.0 |
*Chromosome Mapping | 2 | 0.0 |
Chromosomes, Human, Pair 11/*genetics | 3 | 1.0 |
DNA, Complementary | 2 | 0.0 |
Genetic Markers | 4 | 0.0 |
Genomic Library | 2 | 0.0 |
Hybrid Cells | 3 | 0.0 |
In Situ Hybridization, Fluorescence | 2 | 0.0 |
Granuloma/immunology | 4 | 33.0 |
Immune Tolerance | 4 | 1.0 |
Interleukin-10/*physiology | 2 | 10.0 |
Bacterial Toxins/*immunology | 3 | 37.0 |
Gene Transfer Techniques | 2 | 0.0 |
Gene Frequency | 2 | 0.0 |
Thalassemia/*diagnosis/genetics | 2 | 66.0 |
*Chromosome Deletion | 2 | 0.0 |
Multiple Endocrine Neoplasia Type 1/*genetics | 2 | 1.0 |
Prenatal Diagnosis/*methods | 2 | 1.0 |
alpha-Thalassemia/*diagnosis/genetics | 2 | 100.0 |
Cytotoxicity, Immunologic/*drug effects | 4 | 5.0 |
T-Lymphocytes, Cytotoxic/immunology | 6 | 1.0 |
Cats | 2 | 0.0 |
Haplorhini | 2 | 0.0 |
Rats, Inbred Lew | 2 | 0.0 |
Staphylococcal Food Poisoning/etiology | 2 | 100.0 |
Histocompatibility Antigens Class II/*physiology | 3 | 13.0 |
Colonic Neoplasms/immunology/*therapy | 2 | 50.0 |
Interleukin-2/blood | 2 | 2.0 |
Tumor Necrosis Factor-alpha/metabolism | 3 | 0.0 |
Chimeric Proteins | 2 | 2.0 |
Enterotoxins/*chemistry | 2 | 100.0 |
Superantigens/*chemistry | 2 | 100.0 |
Cytokines/*immunology | 2 | 2.0 |
Immunoglobulin Isotypes | 2 | 12.0 |
HLA-DR Antigens/*immunology | 4 | 3.0 |
Signal Transduction/immunology | 2 | 0.0 |
Antigens, CD40/*physiology | 2 | 5.0 |
Interphase/immunology | 2 | 4.0 |
Tumor Necrosis Factor-alpha/*biosynthesis | 3 | 0.0 |
Point Mutation | 3 | 0.0 |
B-Lymphocytes/immunology | 6 | 0.0 |
Burkitt Lymphoma | 2 | 2.0 |
Immunotherapy, Adoptive | 2 | 2.0 |
Macrophages/immunology | 2 | 0.0 |
Monocytes/immunology | 6 | 1.0 |
Staphylococcus aureus/genetics/immunology | 3 | 100.0 |
Abdomen/ultrasonography | 2 | 66.0 |
Antiplatyhelmintic Agents/therapeutic use | 2 | 100.0 |
Interleukin-1/physiology | 2 | 2.0 |
Protein Synthesis Inhibitors/pharmacology | 2 | 0.0 |
Gene Expression/immunology | 2 | 2.0 |
Staphylococcus/immunology | 3 | 30.0 |
Adjuvants, Immunologic/pharmacology | 2 | 2.0 |
Cell Adhesion/immunology | 3 | 1.0 |
Interleukins/biosynthesis | 3 | 6.0 |
Cytokines/*metabolism | 3 | 1.0 |
Enterotoxins/*immunology/metabolism | 3 | 75.0 |
Recombinant Proteins | 3 | 0.0 |
*Alleles | 2 | 0.0 |
Asia, Southeastern | 5 | 25.0 |
Haplotypes | 2 | 0.0 |
HLA-B27 Antigen/analysis | 3 | 14.0 |
Tomography, X-Ray Computed | 5 | 0.0 |
Leukemia, T-Cell/*immunology | 2 | 11.0 |
Proto-Oncogene Proteins/*genetics | 2 | 0.0 |
Host-Parasite Relations | 3 | 8.0 |
Immunoglobulins/*biosynthesis | 2 | 4.0 |
Morbidity | 4 | 6.0 |
Concanavalin A/immunology | 2 | 11.0 |
Longitudinal Studies | 6 | 0.0 |
Pokeweed Mitogens/immunology | 2 | 15.0 |
Liver Diseases, Parasitic/*immunology | 4 | 100.0 |
Splenic Diseases/*immunology | 3 | 75.0 |
CD4-Positive T-Lymphocytes/immunology | 3 | 0.0 |
CD8-Positive T-Lymphocytes/immunology | 2 | 0.0 |
Clone Cells | 11 | 1.0 |
Gene Expression Regulation | 4 | 0.0 |
Interleukin-1/biosynthesis/genetics | 2 | 7.0 |
Leukemia, Monocytic, Acute/pathology | 2 | 25.0 |
Carbohydrates/immunology | 2 | 16.0 |
Granuloma/*immunology/pathology | 3 | 42.0 |
Schistosoma/*immunology | 2 | 66.0 |
Schistosoma japonicum/immunology | 6 | 66.0 |
Antigens, CD45/analysis | 2 | 0.0 |
Interferon-gamma, Recombinant/pharmacology | 4 | 2.0 |
DNA Primers/genetics | 2 | 0.0 |
Enterotoxins/*toxicity | 4 | 33.0 |
Leukocytes, Mononuclear/drug effects/immunology | 2 | 4.0 |
Immunity, Natural | 7 | 3.0 |
Recombinant Fusion Proteins/*immunology | 2 | 9.0 |
Antigens, Neoplasm/immunology | 5 | 3.0 |
*Gene Expression Regulation | 2 | 0.0 |
Antigens, Differentiation, T-Lymphocyte/immunology | 3 | 1.0 |
Apoptosis/drug effects | 2 | 0.0 |
Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 2 | 2.0 |
Mice, Mutant Strains | 2 | 0.0 |
Receptors, Interleukin-2/biosynthesis | 2 | 1.0 |
T-Lymphocyte Subsets/*drug effects/immunology | 2 | 9.0 |
Antigens, CD2/pharmacology | 2 | 66.0 |
Bronchoalveolar Lavage Fluid/cytology | 2 | 1.0 |
Epithelial Cells | 2 | 0.0 |
Blotting, Northern | 4 | 0.0 |
Chemotaxis, Leukocyte/drug effects | 3 | 3.0 |
Macrophages, Alveolar/drug effects/*physiology | 2 | 33.0 |
Sea Urchins/embryology/*genetics | 2 | 66.0 |
Schistosoma | 2 | 100.0 |
Immunoglobulin E/blood/*immunology | 2 | 33.0 |
DNA Primers/chemistry | 4 | 0.0 |
Thailand | 3 | 2.0 |
Antigens, CD3/immunology | 2 | 0.0 |
Antigens, CD4/immunology | 2 | 1.0 |
Antigens, CD8/immunology | 2 | 2.0 |
Interleukin-4/*biosynthesis | 2 | 3.0 |
Antibodies, Helminth/analysis | 3 | 75.0 |
Hydrogen-Ion Concentration | 2 | 0.0 |
Bacterial Proteins/genetics | 2 | 2.0 |
Superantigens/genetics | 2 | 100.0 |
Proto-Oncogene Protein c-met | 2 | 1.0 |
Posture | 2 | 2.0 |
Sequence Deletion | 2 | 0.0 |
Thailand/epidemiology | 3 | 5.0 |
*Gene Expression | 2 | 0.0 |
Interleukin-2/biosynthesis/genetics | 2 | 5.0 |
*Immunity, Cellular | 3 | 2.0 |
Liver Diseases/immunology | 2 | 13.0 |
Pancreatic Elastase/*blood | 2 | 10.0 |
Triglycerides/blood | 2 | 0.0 |
Cell Count | 2 | 0.0 |
Swine | 2 | 0.0 |
Age Distribution | 2 | 0.0 |
Likelihood Functions | 2 | 1.0 |
*Cytotoxicity, Immunologic | 3 | 0.0 |
Immunoglobulins, Fab/analysis | 2 | 18.0 |
Isoelectric Focusing | 3 | 0.0 |
Models, Structural | 3 | 1.0 |
Acquired Immunodeficiency Syndrome/*immunology | 2 | 0.0 |
CD4-Positive T-Lymphocytes/cytology/*immunology | 2 | 3.0 |
*Fluorescent Dyes | 2 | 6.0 |
Antigens, Bacterial/pharmacology | 3 | 37.0 |
HLA-D Antigens/*immunology | 5 | 8.0 |
Enterotoxins/immunology/*therapeutic use | 2 | 100.0 |
Immunoglobulins, Fab/immunology/*therapeutic use | 3 | 100.0 |
Mice, Nude | 2 | 0.0 |
Superantigens/immunology/*therapeutic use | 2 | 100.0 |
Superantigens/*administration & dosage/immunology | 2 | 100.0 |
Immunoglobulin G/*biosynthesis | 2 | 5.0 |
Immunoglobulin M/biosynthesis | 2 | 2.0 |
Immunologic Tests | 2 | 6.0 |
Receptors, Antigen, T-Cell/physiology | 6 | 4.0 |
T-Lymphocytes/*drug effects | 2 | 2.0 |
Macaca mulatta | 2 | 0.0 |
Antibodies, Monoclonal/*therapeutic use | 3 | 0.0 |
Colonic Neoplasms/immunology/metabolism/*therapy | 2 | 100.0 |
Recombinant Fusion Proteins/*therapeutic use | 3 | 15.0 |
Transplantation, Heterologous | 2 | 0.0 |
Antigens, CD58 | 2 | 1.0 |
HLA-DR Antigens/genetics/immunology | 2 | 6.0 |
Signal Transduction/physiology | 2 | 0.0 |
Receptors, Antigen, T-Cell, alpha-beta/genetics | 2 | 2.0 |
NF-kappa B/physiology | 2 | 2.0 |
Proteins/*chemistry | 2 | 2.0 |
Genetic Screening | 2 | 0.0 |
*Mutation | 2 | 0.0 |
Antigens, Bacterial/immunology | 6 | 5.0 |
Antigens, CD/analysis | 3 | 0.0 |
Macrophages/*immunology | 2 | 0.0 |
Brazil | 4 | 1.0 |
Socioeconomic Factors | 2 | 1.0 |
Headache/etiology | 2 | 20.0 |
Lymphocytes/drug effects/*immunology | 2 | 4.0 |
Seawater | 3 | 30.0 |
Histocompatibility Antigens Class II | 2 | 4.0 |
Biotin/metabolism | 2 | 8.0 |
Peptides/immunology | 2 | 1.0 |
Receptors, Antigen, T-Cell/*immunology | 3 | 1.0 |
Binding, Competitive | 8 | 0.0 |
Immunoglobulin E/biosynthesis | 3 | 7.0 |
*Altitude | 4 | 6.0 |
Injections, Intravenous | 2 | 0.0 |
Schistosoma mansoni | 6 | 60.0 |
Th2 Cells/immunology | 2 | 1.0 |
Cytotoxicity, Immunologic/*immunology | 2 | 4.0 |
Interleukin-2/metabolism | 2 | 1.0 |
RNA, Messenger | 2 | 0.0 |
Schistosomiasis/*immunology | 13 | 76.0 |
Defibrillators, Implantable | 2 | 66.0 |
Aging | 2 | 0.0 |
Enterotoxins/administration & dosage | 2 | 100.0 |
Neoplasms, Experimental/*therapy | 2 | 8.0 |
Hemoglobins, Abnormal/*genetics | 4 | 21.0 |
Immunotherapy/methods | 2 | 2.0 |
*Brain Mapping | 2 | 4.0 |
Cell Line, Tumor | 4 | 0.0 |
T-Lymphocytes, Cytotoxic/drug effects/immunology | 2 | 20.0 |
Schistosomiasis mansoni/*immunology/pathology | 3 | 50.0 |
Postoperative Complications | 2 | 1.0 |
Intercellular Adhesion Molecule-1 | 4 | 1.0 |
Interleukin-1/*biosynthesis | 2 | 1.0 |
Mitogens/pharmacology | 5 | 1.0 |
Antigens, Bacterial/administration & dosage | 2 | 50.0 |
DNA/genetics | 4 | 0.0 |
Immunosorbent Techniques | 3 | 1.0 |
Biological Markers/blood | 5 | 0.0 |
*Antigens, Helminth | 2 | 50.0 |
Hypersensitivity, Delayed/immunology | 2 | 3.0 |
Lymphokines/biosynthesis | 3 | 2.0 |
Exons | 2 | 0.0 |
Mutation/genetics | 2 | 0.0 |
DNA, Neoplasm/genetics/isolation & purification | 2 | 1.0 |
Gene Amplification/*genetics | 2 | 1.0 |
Antigens, CD8/analysis | 3 | 1.0 |
T-Lymphocytes, Suppressor-Effector/*immunology | 3 | 3.0 |
Receptors, Antigen, T-Cell | 2 | 5.0 |
T-Lymphocytes/*physiology | 3 | 1.0 |
Cell Membrane/drug effects | 2 | 5.0 |
Uganda/epidemiology | 2 | 8.0 |
Calcimycin/pharmacology | 3 | 1.0 |
Allergens/*immunology | 2 | 2.0 |
Exotoxins/*immunology | 2 | 18.0 |
Antigens/*immunology | 2 | 2.0 |
Cytotoxicity Tests, Immunologic | 2 | 0.0 |
HLA-DR Antigens | 3 | 0.0 |
Subdural Space | 2 | 66.0 |
T-Lymphocytes/drug effects/immunology | 2 | 2.0 |
Adsorption | 2 | 1.0 |
Rats, Wistar | 3 | 0.0 |
Spinal Cord/pathology | 2 | 2.0 |
Staphylococcal Infections/diagnosis | 2 | 100.0 |
HLA-DP Antigens/*metabolism | 2 | 100.0 |
HLA-DQ Antigens/*metabolism | 2 | 50.0 |
Isoantigens/immunology | 2 | 2.0 |
HLA-DR Antigens/physiology | 2 | 18.0 |
Epitopes | 4 | 0.0 |
Serologic Tests | 2 | 2.0 |
Multivariate Analysis | 3 | 0.0 |
Carcinoma/*immunology | 2 | 6.0 |
Colonic Neoplasms/*immunology | 2 | 8.0 |
Histocompatibility Antigens Class II/analysis | 2 | 1.0 |
RNA, Messenger/genetics/metabolism | 2 | 0.0 |
Restriction Mapping | 3 | 0.0 |
Interferon Inducers/*immunology | 2 | 100.0 |
T-Lymphocytes/drug effects | 2 | 3.0 |
Antibodies, Monoclonal/*diagnostic use | 2 | 0.0 |
Antigens, CD3 | 4 | 0.0 |
Superantigens/administration & dosage | 2 | 66.0 |
*Immunotoxins | 2 | 16.0 |
Schistosomiasis japonica/immunology | 3 | 100.0 |
Enterotoxins/*isolation & purification | 2 | 50.0 |
Antigens, CD28 | 2 | 1.0 |
Antigens, Differentiation, T-Lymphocyte/*immunology | 2 | 0.0 |
*Guanylate Cyclase | 3 | 50.0 |
*Receptors, Peptide | 3 | 12.0 |
Enterotoxins/*metabolism/pharmacology | 3 | 75.0 |
Rats, Inbred Strains | 3 | 0.0 |
Antigens, Differentiation, T-Lymphocyte/physiology | 2 | 2.0 |
Angina Pectoris/blood/physiopathology | 2 | 66.0 |
Chest Pain/blood/physiopathology | 2 | 100.0 |
Thioredoxin/*blood | 3 | 37.0 |
Antigens, CD/*analysis | 2 | 0.0 |
Antigens, CD45 | 4 | 1.0 |
Histocompatibility Antigens/*analysis | 2 | 4.0 |
Bacteriophage Typing | 2 | 25.0 |
Diarrhea/microbiology | 2 | 14.0 |
Drug Resistance, Microbial | 3 | 1.0 |
Antigens, CD4/*analysis | 2 | 1.0 |
Syndrome | 3 | 0.0 |
*Heterozygote Detection | 2 | 1.0 |
Thalassemia/*genetics | 2 | 9.0 |
False Negative Reactions | 2 | 1.0 |
Cell Survival/drug effects | 2 | 0.0 |
*Enzyme-Linked Immunosorbent Assay | 6 | 7.0 |
*Precipitin Tests | 3 | 42.0 |
Venezuela/epidemiology | 3 | 17.0 |
Larva/immunology | 3 | 42.0 |
Immunoglobulin Idiotypes/immunology | 3 | 13.0 |
Mitogens/*pharmacology | 2 | 1.0 |
T-Lymphocytes/*drug effects/immunology | 2 | 2.0 |
*Methicillin Resistance | 2 | 28.0 |
*Proto-Oncogenes | 2 | 0.0 |
Antineoplastic Agents/*pharmacology | 3 | 0.0 |
Chromatography, Gel | 2 | 0.0 |
DNA Replication/drug effects | 5 | 2.0 |
Enterotoxins/immunology/*pharmacology | 2 | 100.0 |
Concanavalin A | 2 | 4.0 |
*Gene Amplification | 2 | 0.0 |
Skin/pathology | 2 | 0.0 |
Chi-Square Distribution | 3 | 0.0 |
Antigens, Helminth/*diagnostic use | 2 | 66.0 |
Staphylococcus | 3 | 60.0 |
L Cells (Cell Line) | 3 | 1.0 |
Leukocytes/immunology | 4 | 3.0 |
Immunodiffusion | 4 | 1.0 |
Enterotoxins/analysis/*immunology | 2 | 66.0 |
Chromatography, Affinity | 5 | 0.0 |
Schistosomiasis/drug therapy/*immunology | 2 | 100.0 |
Splenomegaly/immunology | 2 | 40.0 |
Milk/*microbiology | 3 | 100.0 |
Cell Differentiation | 2 | 0.0 |
Immunoglobulin Idiotypes/*analysis | 2 | 28.0 |
Schistosomiasis japonica/drug therapy/*immunology | 2 | 100.0 |
T-Lymphocytes/drug effects/*immunology/metabolism | 2 | 8.0 |
Laminectomy | 2 | 22.0 |
Immunoglobulins, Fab/immunology | 2 | 1.0 |
Spleen/cytology | 5 | 2.0 |
Epitopes/analysis | 3 | 1.0 |
Schistosoma/immunology | 2 | 66.0 |
Coturnix | 2 | 8.0 |
Culture Media | 2 | 0.0 |
Staphylococcal Food Poisoning/microbiology | 3 | 100.0 |
Chromosome Deletion | 3 | 0.0 |
DNA/analysis | 2 | 0.0 |
Asian Continental Ancestry Group/genetics | 2 | 0.0 |
Antigens, Bacterial | 2 | 7.0 |
Thymidine/metabolism | 2 | 0.0 |
Chemical Fractionation | 2 | 2.0 |
Ovum/immunology/physiology | 2 | 100.0 |
Schistosoma mansoni/immunology/*physiology | 2 | 100.0 |
Lectins/pharmacology | 2 | 5.0 |
Immunoglobulin Idiotypes/*immunology | 2 | 5.0 |
Dyes | 2 | 1.0 |
*Magnetic Resonance Imaging | 2 | 1.0 |
Histamine/*pharmacology | 2 | 5.0 |
Lasers | 2 | 1.0 |
Glycoproteins/immunology | 2 | 2.0 |
Receptors, Interleukin-2 | 4 | 3.0 |
Spleen/*immunology | 2 | 9.0 |
*Antibody Formation | 2 | 2.0 |
Killer Cells, Natural/*immunology | 2 | 0.0 |
Interferon Type I/pharmacology | 3 | 6.0 |
Lymphocytes/*immunology | 4 | 0.0 |
Antibodies/analysis | 4 | 3.0 |
Chromatography | 2 | 1.0 |
DNA/biosynthesis | 2 | 0.0 |
Interleukin-2/*biosynthesis/metabolism | 2 | 40.0 |
Immunosuppressive Agents/pharmacology | 3 | 1.0 |
Immunoglobulin A/analysis | 2 | 1.0 |
Interferon Inducers | 2 | 100.0 |
Intradermal Tests | 5 | 21.0 |
Liver Diseases, Parasitic/*immunology/pathology | 2 | 50.0 |
Erythrocytes/immunology | 2 | 0.0 |
Antigens/immunology | 4 | 2.0 |
Schistosoma haematobium/immunology | 5 | 83.0 |
Methods | 2 | 0.0 |
*Immunoenzyme Techniques | 3 | 2.0 |
Antigens | 3 | 3.0 |
Spleen/*metabolism | 2 | 13.0 |
Tissue Extracts/pharmacology | 2 | 8.0 |
Antigens/*isolation & purification | 2 | 25.0 |
Schistosomiasis/*diagnosis/immunology | 3 | 100.0 |
*Antigens | 2 | 10.0 |
Probability | 2 | 0.0 |
Immunoassay/*methods | 2 | 2.0 |
